Norethisterone enanthate
Progestin; Progestogen ester | |
ATC code | |
---|---|
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Norethisterone enanthate (NETE), also known as norethindrone enanthate, is a form of
Side effects include
Norethisterone was patented in 1951 and NETE came into medical use in 1957.[7][8] It is on the World Health Organization's List of Essential Medicines.[9] It has been approved by itself in more than 60 countries including the United Kingdom and some in Europe, Central America, and Africa, and in combination with estradiol valerate in at least 36 countries mainly in Latin America.[4][10][11][12] It is not available in the United States.[10]
Medical uses
NETE is used on its own as a long-lasting progestogen-only injectable contraceptive in women.[1][5] It is administered via intramuscular injection once every two months.[1][5]
Contraindications
Side effects
Side effects of NETE may include breast pain, headaches, depression, irregular menstrual periods, and pain at the site of injection.[5] It can cause birth defects in the fetus if used during pregnancy.[1]
Overdose
Interactions
Pharmacology
Pharmacodynamics
NETE is a prodrug of norethisterone in the body.[13] Upon reaching circulation, it is rapidly converted into norethisterone by esterases. Hence, as a prodrug of norethisterone, NETE has essentially the same effects as norethisterone, acting as a potent progestogen with additional weak androgenic and estrogenic activity (the latter via its metabolite ethinylestradiol).[14] NETA has some progestogenic activity of its own, but it is unclear if NETE does similarly.[13]
NETE is of about 38% higher
Compound | Typea | PR | AR | ER | GR | MR | SHBG | CBG
|
---|---|---|---|---|---|---|---|---|
Norethisterone | – | 67–75 | 15 | 0 | 0–1 | 0–3 | 16 | 0 |
5α-Dihydronorethisterone | Metabolite | 25 | 27 | 0 | 0 | ? | ? | ? |
3α,5α-Tetrahydronorethisterone | Metabolite | 1 | 0 | 0–1 | 0 | ? | ? | ? |
3α,5β-Tetrahydronorethisterone | Metabolite | ? | 0 | 0 | ? | ? | ? | ? |
3β,5α-Tetrahydronorethisterone | Metabolite | 1 | 0 | 0–8 | 0 | ? | ? | ? |
Ethinylestradiol | Metabolite | 15–25 | 1–3 | 112 | 1–3 | 0 | 0.18 | 0 |
Norethisterone acetate | Prodrug | 20 | 5 | 1 | 0 | 0 | ? | ? |
Norethisterone enanthate | Prodrug | ? | ? | ? | ? | ? | ? | ? |
Noretynodrel | Prodrug | 6 | 0 | 2 | 0 | 0 | 0 | 0 |
Etynodiol | Prodrug | 1 | 0 | 11–18 | 0 | ? | ? | ? |
Etynodiol diacetate | Prodrug | 1 | 0 | 0 | 0 | 0 | ? | ? |
Lynestrenol | Prodrug | 1 | 1 | 3 | 0 | 0 | ? | ? |
Notes: Values are percentages (%). Reference , or neither of norethisterone. Sources: See template. . Footnotes: a = |
Compound | Form | Dose for specific uses (mg)[c] | DOA[d] | |||
---|---|---|---|---|---|---|
TFD[e] | POICD[f] | CICD[g] | ||||
Algestone acetophenide | Oil soln. | - | – | 75–150 | 14–32 d | |
Gestonorone caproate | Oil soln. | 25–50 | – | – | 8–13 d | |
Hydroxyprogest. acetate[h] | Aq. susp. | 350 | – | – | 9–16 d | |
Hydroxyprogest. caproate | Oil soln. | 250–500[i] | – | 250–500 | 5–21 d | |
Medroxyprog. acetate | Aq. susp. | 50–100 | 150 | 25 | 14–50+ d | |
Megestrol acetate | Aq. susp. | - | – | 25 | >14 d | |
Norethisterone enanthate | Oil soln. | 100–200 | 200 | 50 | 11–52 d | |
Progesterone | Oil soln. | 200[i] | – | – | 2–6 d | |
Aq. soln. | ? | – | – | 1–2 d | ||
Aq. susp. | 50–200 | – | – | 7–14 d | ||
Notes and sources:
|
A single intramuscular injection of
Pharmacokinetics
A single
Similarly to oral norethisterone and
Chemistry
NETE, also known as norethinyltestosterone enanthate, as well as 17α-ethynyl-19-nortestosterone 17β-enanthate or 17α-ethynylestr-4-en-17β-ol-3-one 17β-enanthate, is a progestin, or
History
NETE was introduced by Schering as Noristerat in 1957.[8] It was the second long-acting progestogen to be used clinically, after hydroxyprogesterone caproate.[38] The medication was the first progestogen-only injectable contraceptive, preceding medroxyprogesterone acetate (Depo-Provera).[8]
Society and culture
Generic names
Norethisterone enantate is the
Brand names
NETE has been marketed alone as a
Composition | Dose | Brand names | Use |
---|---|---|---|
NET only | Low (e.g., 0.35 mg) | Multiple[a] | Progestogen-only oral contraceptive
|
NET or NETA only | High (e.g., 5 mg, 10 mg) | Multiple[b] | Gynecological disorders and other uses
|
NETE only | Injection (e.g., 200 mg) | Multiple[c] | Progestogen-only injectable contraceptive |
NET or NETA with ethinylestradiol | Low (e.g., 0.4 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg) | Multiple[d] | Combined oral contraceptive
|
NET with mestranol | Low (e.g., 1 mg, 2 mg) | Multiple[e] | Combined oral contraceptive |
NETA with estradiol | Low (e.g., 0.1 mg, 0.5 mg) | Multiple[f] | Combined menopausal hormone therapy
|
NETE with estradiol valerate | Injection (e.g., 50 mg) | Multiple[g] | Combined injectable contraceptive
|
Abbreviations: NET = Norethisterone. NETA = Norethisterone acetate. NETE = Norethisterone enanthate. Sources: [43][44] [37][45] Notes:
|
Availability
NETE has been approved for use alone as a progestogen-only injectable contraceptive in more than 60 countries throughout the world including in Europe, Latin America, Asia, and Africa.[4][10][11] Specific countries in which NETE as a standalone medication is or has been available include Bangladesh, France, Germany, India, Italy, Malaysia, Mexico, the Philippines, Singapore, South Africa, Thailand, and the United Kingdom.[37][40][41][42]
NETE has been approved for use in combination with
NETE is not available in any form in the United States.[10]
Research
NETE was studied by Schering for use as a progestogen-only injectable contraceptive at a dose of 25 mg once a month but produced poor cycle control with this regimen and was not marketed.[46]
NETE has been studied for use as a potential male hormonal contraceptive in combination with testosterone in men.[47]
See also
References
- ^ a b c d e f g h i j k "Noristerat 200mg, solution for intramuscular injection - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Archived from the original on 31 December 2016. Retrieved 31 December 2016.
- ^ ISBN 978-1-4757-2085-3. Archivedfrom the original on 5 November 2017.
- ISBN 978-3-88763-075-1. Archivedfrom the original on 28 May 2013. Retrieved 30 May 2012.
- ^ ISBN 9780309041478. NAP:14119.
- ^ ISBN 9789241547659.
- S2CID 12856674.
- ISBN 9783527607495. Archivedfrom the original on 2016-12-20.
- ^ ISBN 978-1-57607-181-6. Archivedfrom the original on 2017-11-05.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ ISBN 978-1-4614-6579-9. Archivedfrom the original on 5 November 2017.
- ^ ISSN 2278-4357. Archived from the original(PDF) on 2017-08-10. Retrieved 2018-08-02.
- ^ PMID 12290848.
- ^ PMID 15491776.
- ^ ISBN 978-92-832-1291-1. Archivedfrom the original on 2017-11-05.
Norethisterone and its acetate and enanthate esters are progestogens that have weak estrogenic and androgenic properties.
- ISBN 978-3-662-00942-0.
- ISBN 978-3-642-95583-9.
- ISBN 978-3-642-96158-8.
- ISBN 978-94-009-8195-9.
- ISBN 9783110006148.
17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce secretory changes in primed endometrium is about 250 mg. per menstrual cycle.
- ISBN 978-3-11-150424-7.
- OCLC 278011135.
- ISBN 978-0-8247-8291-7.
- ISBN 978-0-12-137250-7.
- PMID 8013220.
- PMID 8013216.
- ISBN 978-1-4613-2241-2.
- PMID 6452729.
- PMID 6223851.
- ISBN 978-1-4614-0554-2.
- ^ Chu YH, Li Q, Zhao ZF (April 1986). "Pharmacokinetics of megestrol acetate in women receiving IM injection of estradiol-megestrol long-acting injectable contraceptive". The Chinese Journal of Clinical Pharmacology.
The results showed that after injection the concentration of plasma MA increased rapidly. The meantime of peak plasma MA level was 3rd day, there was a linear relationship between log of plasma MA concentration and time (day) after administration in all subjects, elimination phase half-life t1/2β = 14.35 ± 9.1 days.
- ISBN 978-3-642-73790-9.
- ISBN 978-1-84214-071-0.
- ISBN 978-1-284-02542-2.
- ^ a b c d del Cisne Valle Alvarez D (11 May 2011). Efecto de una Dosis de 50 mg de Enantato de Noretisterona y 5 mg de Valerato de Estradiol en los Niveles de Testosterona Total en Hombres Mexicanos Sanos [Effect of a Dose of 50 mg of Norethisterone Enanthate and 5 mg of Estradiol Valerate on Total Testosterone Levels in Healthy Mexican Men] (MSc). National Polytechnic Institute of Mexico.
- ^ S2CID 3813229.
- OCLC 278011135.
- ^ ISBN 978-3-88763-075-1.
- PMID 13583829.
- ^ ISBN 978-94-011-4439-1.
- ^ a b c d e f "Norethisterone".
- ^ ISBN 978-0-85369-840-1.
- ^ a b c "Micromedex Products: Please Login".
- ^ "Norethisterone". Drugs.com.
- ^ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Archived from the original on 16 November 2016. Retrieved 27 November 2016.
- ISBN 978-92-832-1272-0.
- PMID 865726.
- PMID 20933120.
External links
- "Norethisterone Enanthate". Drug Information Portal. U.S. National Library of Medicine.